TrialJournal for immunotherapy of cancer2022

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.

Siming Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.